Literature DB >> 31657725

Spironolactone plus patiromer: proceed with caution.

Calyani Ganesan1, Alan C Pao2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31657725      PMCID: PMC9048092          DOI: 10.1016/S0140-6736(19)32485-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

2.  Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Authors:  David A Bushinsky; David M Spiegel; Jinwei Yuan; Suzette Warren; Jeanene Fogli; Pablo E Pergola
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-31       Impact factor: 8.237

3.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

4.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Rajiv Agarwal; Patrick Rossignol; Alain Romero; Dahlia Garza; Martha R Mayo; Suzette Warren; Jia Ma; William B White; Bryan Williams
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

5.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

  5 in total
  2 in total

1.  Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.

Authors:  D Banerjee; P Winocour; T A Chowdhury; P De; M Wahba; R Montero; D Fogarty; A H Frankel; J Karalliedde; P B Mark; D C Patel; A Pokrajac; A Sharif; S Zac-Varghese; S Bain; I Dasgupta
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388

2.  Personalizing potassium management in patients on haemodialysis.

Authors:  Rosa D Wouda; Liffert Vogt; Ewout J Hoorn
Journal:  Nephrol Dial Transplant       Date:  2021-01-01       Impact factor: 5.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.